Page last updated: 2024-09-05

sb 203580 and nicorandil

sb 203580 has been researched along with nicorandil in 2 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(nicorandil)
Trials
(nicorandil)
Recent Studies (post-2010) (nicorandil)
3,48941,1371,487207428

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aggeli, IK; Beis, I; Gaitanaki, C; Iliodromitis, EK; Kremastinos, DT; Tsiafoutis, I; Zoga, A1
Li, J; Wang, H; Xiao, Y; Xie, W; Yu, Y; Zuo, X1

Other Studies

2 other study(ies) available for sb 203580 and nicorandil

ArticleYear
p38-MAPK is involved in restoration of the lost protection of preconditioning by nicorandil in vivo.
    European journal of pharmacology, 2008, Jan-28, Volume: 579, Issue:1-3

    Topics: Animals; Anti-Arrhythmia Agents; Cyclic GMP; Imidazoles; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nicorandil; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Potassium Channels; Protein Kinase C; Pyridines; Rabbits; Signal Transduction

2008
Protective effect of nicorandil on hypoxia‑induced apoptosis in HPAECs through inhibition of p38 MAPK phosphorylation.
    Molecular medicine reports, 2013, Volume: 7, Issue:3

    Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Hypoxia; Cells, Cultured; Endothelial Cells; Humans; Imidazoles; Nicorandil; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Vasodilator Agents

2013